Table 2.

Contribution of maraviroc at 24 weeks to viral suppression based on overall susceptibility score of phase III maraviroc studies (Gulick et al 2007d)

Combined analyses of MOTIVATE 1 and MOTIVATE 2 results at 24 weeks
Number of active agents in OBT based on overall susceptibility score	HIV-1 viral load <50 copies/mL (%)
	Placebo + OBT	MVC once daily + OBT	MVC twice daily + OBT
0	3	18	29
1	9	43	43
2	19	52	53
≥3	55	61	58

Abbreviations: MVC, maraviroc; OBT, optimized background therapy.